Argenx stock holds near recent highs as half year 2026 update and Forte deal shape outlook
Published on 08/13/2026 at 10:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx SE (ISIN NL0010832176) stock is trading near recent highs, with its Nasdaq-listed American Depositary Shares closing at $875.77 on August 12, 2026, up 1.28% for the day according to market data from TradingKey, as investors weigh the latest half year 2026 update and a pending acquisition in the US biotech space.
Half year 2026 results and business update
Per the regulated news section on Argenx SE's Euronext profile, the company reported its half year 2026 financial results and provided a second quarter business update on July 23, 2026, giving investors the most recent look at its revenue and pipeline progress.
While the detailed figures are contained in the full report, the timing means these half year 2026 numbers fall well inside the freshness window for fundamentals as of August 13, 2026 and represent the latest officially reported metrics on Argenx's topline and profitability, offering a current baseline for valuation discussions.
Forte Biosciences acquisition and CD122 antibody potential
The same Euronext overview shows that Argenx announced on July 27, 2026 an agreement to acquire Forte Biosciences, Inc., adding the first-in-class anti-CD122 antibody FB102 to its portfolio, and followed up on August 6, 2026 with the commencement of the tender offer to complete the transaction, highlighting a clear strategic move to expand its immunology pipeline.
For US investors following Argenx's Nasdaq listing, the Forte Biosciences deal introduces a new mechanism of action that can complement the company's existing antibody programs and potentially diversify future revenue streams once the FB102 asset advances through clinical development, although concrete commercial timelines still depend on trial outcomes and regulatory review.
More background on Argenx stock
Read additional coverage and regulatory news on Argenx to better understand how the half year 2026 update and Forte Biosciences acquisition shape the company's pipeline and stock narrative.
Representative product: efgartigimod for autoimmune diseases
A representative product from Argenx's portfolio is efgartigimod, an Fc fragment engineered to reduce pathogenic IgG antibodies and already used in treating certain autoimmune indications, illustrating the company's focus on antibody-based therapies that modulate the immune system.
Stock level and market context
As of the $875.77 close on August 12, 2026 cited by TradingKey, Argenx's Nasdaq-listed ADRs trade at a level that reflects substantial value creation compared with earlier years, even though specific historical prices and detailed revenue and earnings figures from the half year 2026 report remain in the underlying filings and investor presentations.
Argenx stock at a glance
- Company: Argenx SE
- ISIN: NL0010832176
- Ticker: ARGX
- Exchange: Nasdaq (ADR) and Euronext Brussels
- Price (as of August 12, 2026, 4:00 p.m. ET): $875.77 USD
- Sector / Industry: Health Care / Biotechnology
- Index membership: not specified
- Next earnings date: not yet officially scheduled
